# Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

> **NCT00456807** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Cervarix TM

## Key facts

- **NCT ID:** NCT00456807
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456807, "Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00456807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*